Table 4.
Section | Questions | Abanobi et al,43 2015 | Cary et al,42 2016 | Desouzart et al,17 2016 | Gordon et al,13 2007 | |
Reporting | 1 | Is the hypothesis/aim/objective of the study clearly described? | Y | Y | Y | Y |
2 | Are the main outcomes to be measured clearly described in the Introduction or Methods section? | N | Y | Y | Y | |
3 | Are the characteristics of the patients included in the study clearly described? | Y | N | Y | X | |
4 | Are the interventions of interest clearly described? | X | X | Y | X | |
5 | Are the distributions of principal confounders in each group of subjects to be compared clearly described? | *Y | X | *Y | *Y | |
6 | Are the main findings of the study clearly described? | Y | Y | Y | Y | |
7 | Does the study provide estimates of the random variability in the data for the main outcomes? | Y | Y | Y | Y | |
8 | Have all important adverse events that may be a consequence of the intervention been reported? | X | X | N | X | |
9 | Have the characteristics of patients lost to follow-up been described? | X | X | Y | X | |
10 | Have actual probability values been reported (eg, 0.035 rather than<0.05) for the main outcomes except where the probability value is less than 0.001? | Y | Y | Y | N | |
External validity | 11 | Were the subjects asked to participate in the study representative of the entire population from which they were recruited? | Y | Y | N | Y |
12 | Were those subjects who were prepared to participate representative of the entire population from which they were recruited? | U | N | N | N | |
13 | Were the staff, places and facilities where the patients were treated, representative of the treatment the majority of patients receive? | X | X | Y | X | |
Internal validity: bias | 14 | Was an attempt made to blind study subjects to the intervention they have received? | X | X | U | X |
15 | Was an attempt made to blind those measuring the main outcomes of the intervention? | X | X | N | X | |
16 | If any of the results of the study were based on ‘data dredging’, was this made clear? | Y | Y | Y | Y | |
17 | In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case–control studies, is the time period between the intervention and outcome the same for cases and controls? | Y | X | Y | X | |
18 | Were the statistical tests used to assess the main outcomes appropriate? | Y | Y | Y | Y | |
19 | Was compliance with the intervention/s reliable? | X | X | U | X | |
20 | Were the main outcome measures used accurate (valid and reliable)? | Y | Y | Y | Y | |
Internal validity: confounding | 21 | Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case–control studies) recruited from the same population? | Y | X | Y | Y |
22 | Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case–control studies) recruited over the same period of time? | Y | X | Y | X | |
23 | Were study subjects randomised to intervention groups? | X | X | Y | X | |
24 | Was the randomised intervention assignment concealed from both patients and healthcare staff until recruitment was complete and irrevocable? | X | X | U | X | |
25 | Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? | N | N | N | Y | |
26 | Were losses of patients to follow-up taken into account? | X | X | Y | X | |
Power | 27 | Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%? | N | X | N | N |
Score | 14/17 | 9/12 | 19/28 | 12/14 | ||
Percentage | 82 | 75 | 68 | 86 |
N = no = 0 points, Y = yes = 1 points, *Y = 2 points, U = unable to determine = 0, X = not applicable (see Quality of Evidence section).
Evidence levels = strong (>75%), moderate (50%–74%), limited (25%–49%) and poor quality (<24%).47